

Comparative cross-sectional study evaluating four different single antibiotic prophylaxis in orthopedic surgeries for prevention of surgical site infection

Hisham El Nahhas

Tanta University, Egypt

Background: Surgical site infection prevalence is estimated to be 7.81% in developing and African countries

This problem adds to pre-existing health problems and worsens the cost of care in hospitals. It must be studied well in any country suffering from extensive health and economic problems. The best method to handle such a problem is to prevent it, and so the World Health Organization mentioned six measures to prevent it, and of these measures, the prophylactic antibiotic use and selection is what concerns us as clinical pharmacists. As different and variable types of infection and susceptibility patterns exist in Egypt, a study evaluating the different antibiotics used for that purpose will aid in improving clinical and economical outcomes.

Method: In this cross-sectional study, 69 patients who had orthopedic surgeries in 6 different hospitals in the Egyptian Delta area were studied after they matched the inclusion criteria, and their medical records were used while maintaining their confidentiality and anonymity. There were 4 prophylactic

antibiotics (Cefazolin, Cefotaxime, Ceftriaxone, and Vancomycin) used, and a comparative statistical analysis was done.

Results: showed that 75% of patients who received Vancomycin developed surgical site infection with a statistically significant association (P value <0.001). The highest effective antibiotics with statistically significant association were Cefotaxime, followed by Ceftriaxone, where 8.3% and 14.3% developed surgical site infection after orthopedic surgeries, (P value = 0.04 and 0.02) respectively. 25% of patients treated with Cefazolin developed surgical site infection without significant association (p value = 0.515).

Conclusion: This is to say that according to this study, in Egyptian hospitals and among these four antibiotics, cefotaxime is the best and vancomycin is the worst antibiotic used in orthopedic surgical site infection prophylaxis.

Key words: surgical site infection, antibiotic prophylaxis, vancomycin, cefotaxime.

Received Date: October 15, 2022; **Accepted Date:** October 17, 2022; **Published Date:** October 31, 2022

Public uptake of the first and second COVID-19 vaccines doses and their experiences and attitudes towards COVID-19 prevention strategies

Mansour A Mahmoud

Taibah University, Saudi Arabia

Objective: To investigate public uptake of the first and second COVID-19 vaccines doses and their experiences and attitudes towards COVID-19 prevention strategies.

Methods: This was a national cross-sectional web-based study conducted in the period from 30/12/2021 to 26/1/2022. A self-administered survey was prepared from a literature search and information about COVID-19 available at various resources. The developed questionnaire was validated for readability by experts and refined in light of the feedbacks received from the experts and the final survey was prepared. The reliability of the questionnaire was 0.7 which shows an acceptable level of scale internal consistency. The data analysis was performed using IBM SPSS software.

Results: A total of 513 participants completed the survey, including 311(60.6%) women and 202(39.4%) men. Most participants were below 31 years of age 273(53.2%).

The mean age was (31.5±12.8) years. It was found that, 193(37.9%) were previously diagnosed with COVID-19, 493(96.1%) took the first and second dose of COVID-19, 100 (19.5%) were diagnosed with COVID-19 after taking the first and second dose of the vaccines and 376 (73.3%) suffered from side effects, of these 14% (56/376) reported the side effects to the health authorities. The most common side effect was general body pain (51.5%), fever (42.3%), headache (39.5%), and injection site pain (37.6%). The most commonly used vaccine was Pfizer (73.6%). Participants who are >31 years old had statistically significant positive attitude towards preventive measures compared to those ≤ 31 years (P=0.009). Conclusion: Vaccine uptake was massive; few cases were infected with COVID-19 after vaccination and Side effects due to COVID-19 vaccine were common. Majority of the participants had positive to moderate attitude towards COVID 19 preventive measures.

Received Date: October 01, 2022; **Accepted Date:** October 03, 2022; **Published Date:** October 31, 2022

Does use of statins aggravate glycemic control in patients with type 2 diabetes: A retrospective cohort study

Tesfay Ephrem

Addis Ababa University, Ethiopia

The main purpose of the study was to assess glycemic control among statin users versus non-users in type 2 diabetes patients for a nine-year follow-up period.

Method: A retrospective cohort study was used on 204 study subjects in Tikur Anbesa Specialized Hospital. Medical records of eligible patients were followed from January 1, 2011 until the occurrence of the outcome, date of administrative censoring or April 24, 2019. An assumption for proportional hazard was met after testing through a graphical method by log minus log curve and the time-dependent Cox-model. A sensitivity analysis and propensity score analysis was also performed. In this propensity-matched cohort, Kaplan-Meier analysis was repeated. An independent samples t-test was used to compare the mean of the continuous variables between the two cohorts. Moreover, incidence rates per 100 person-years were employed to crudely determine rates of the poor glycemic control. Lastly, Cox regression analysis was done to find out the effects of independent variables on the outcome variables.

Result: The mean fasting blood glucose of statin users and non-statin users were 176.2 mg/dL (standard error of mean

[SEM]: 2.9 mg/dL) and 163.9 (SEM: 3.1 mg/dL, respectively. The Kaplan-Meier analysis showed that non-statin users had a better glycemic control than patients who were taking statins at all levels of time (Log Rank Chi-Square=19.1, $p < 0.001$). Besides this, after propensity score matching, there was a statistically significant difference in mean FBG time between statin users and non-statin users ($t_{202} = 2.901$, $p < 0.004$). Concerning the predictors, there were statistically significant difference for glycemic control for ages ranging 50 to 54 years (adjusted hazard ratio [AHR] =0.401; 95% CI [confidence interval]: 0.195–0.823), metformin 1000 mg (AHR=0.410; 95% CI: 0.243–0.693) and simvastatin 40 mg (AHR=0.396; 95% CI:

0.229–0.686) compared to their corresponding controls (75 to 79 years and the absence of the medications, respectively

Conclusion: This study provides a benchmark for assessing the association of statins with poor glycemic control at the comprehensive specialized hospital. Moving forward, we call for the health care providers to closely monitor the glycemic control of diabetic patients taking statins and place a special effort in optimizing the treatment outcome.

Received Date: July 31, 2022; **Accepted Date:** August 03, 2022; **Published Date:** October 31, 2022